fail show benefit
fail show benefit
announc phase trial epacadostat combin keytruda echo-
advanc melanoma fail meet primari endpoint improv
progress free surviv compar monotherapi keytruda accord
independ data monitor committe secondari endpoint overal surviv
os expect reach statist signific either studi discontinu
result manag comment demograph consist histor
trial like contribut failur
trend efficaci biomark data pend
hazard ratio hr ci ci
immatur os suggest favor trend efficaci analyz
biomark detect potenti effect subgroup dont see much hope salvag
asset news certainli disappoint though investor high
expect data readout given melanoma hot tumor lack
efficaci lend support clinic activ tumor type
includ lung kidney cancer believ prudent remov ido complet
valuat addit remov sg earmark
potenti epacadostat launch result increas ep beyond
lack random control trial like blame
absenc random control data phase alway critic
investor hope compani learn lesson although player
difficult teas clinic activ without control arm
high profil binari event undoubtedli dampen investor
sentiment maintain buy given intrins valu jakafi royalti
olumi could provid floor valu upcom catalyst includ gvhd
readout mid-year earli mid-stag pipelin includ fgfr inhibitor
repres potenti upsid remov epacadostat npv updat
po
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu iclusig
cml baricitinib regulatori review us
emerg rich clinic stage
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin baricitinib
approv eu regulatori review ra
us epacadostat ido inhibitor
liquid solid tumor
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi gvhd
baricitinib call olumi ex-u iclusig earli
pipelin also includ approx net cash use wacc
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data epacadostat clinic
trial earlier-than-expect more-than-expect competit jakafi
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
